Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28304921 | 0.89 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1HTTKDM4EPOLB | |
| SCHEMBL4164590 | 0.86 | HTT (0.54) | SMN1; SMN2ALDH1A1HTTKDM4ETSHR | |
| SCHEMBL12141974 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1NPSR1HTTKDM4E | |
| SCHEMBL29944077 | 0.84 | KMT2A (0.53) | SMN1; SMN2ALDH1A1HTTKDM4EMAPT | |
| SCHEMBL22018759 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1NPSR1HTTKDM4E | |
| SCHEMBL9631669 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1NPSR1HTTKDM4E | |
| SCHEMBL855339 | 0.82 | POLB (0.60) | SMN1; SMN2ALDH1A1NPSR1HTTKDM4E | |
| SCHEMBL30073359 | 0.82 | POLB (0.60) | SMN1; SMN2ALDH1A1NPSR1HTTKDM4E | |
| SCHEMBL12844504 | 0.81 | NPSR1 (0.58) | SMN1; SMN2ALDH1A1NPSR1HTTKDM4E | |
| SCHEMBL12775471 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1NPSR1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2008104869-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | SMN1; SMN2 1371/4885ALDH1A1 148/4885NPSR1 1173/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | SMN1; SMN2 1483/4885ALDH1A1 134/4885NPSR1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.